National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19) | Apply Online

Opportunity Summary:

The National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U19) is a National Institutes of Health (NIH) cooperative agreement program designed to push promising medication ideas further and faster by organizing them under coordinated, multidisciplinary research teams. The central purpose is to create integrated partnerships that can discover and develop pharmacological agents to both treat and better understand mental illness as well as drug and alcohol addiction. Rather than supporting isolated projects, this opportunity is built around the idea that modern therapeutics development moves best when basic scientists, translational researchers, clinical investigators, and (when possible) industry development experts work together under a shared plan with clear milestones and a strong emphasis on moving candidates toward real-world testing.

The scientific scope of the program spans the full early pipeline of therapeutics development. It prioritizes accelerating innovative drug discovery, meaning applicants are expected to propose rational, target-driven strategies that can produce new candidate medications or reposition existing ones in a scientifically justified way. A major objective is also the development of pharmacologic tools, such as novel ligands, that can be used in basic and clinical research to characterize existing targets more precisely or validate new targets. In practical terms, this can include compounds, probes, or other chemical/biological tools that help clarify how a target behaves in relevant systems, how strongly and selectively a candidate engages that target, and whether that engagement produces changes that matter for symptoms or disease mechanisms.

Another key emphasis is on building and validating models for evaluating novel therapeutics. That includes preclinical models that better predict clinical response and translational assays that bridge animal and human research. The program is explicitly interested in strengthening the evidence chain that connects a mechanistic hypothesis (target, pathway, circuit, or receptor system) to a measurable pharmacologic effect and then to clinically meaningful outcomes. Applicants are therefore encouraged to include plans for rigorous validation, reproducibility, and decision-making criteria that help determine whether a candidate should advance, be modified, or be stopped.

The opportunity also supports early phase human clinical testing, especially proof-of-concept work that can rapidly assess safety and potential efficacy. This aspect is aimed at shortening the time between preclinical promise and clinical reality by enabling well-designed early studies that test whether a drug candidate (or a new indication for an IND-ready drug) shows signs of benefit in relevant patient populations. The emphasis on "IND-ready" new indications highlights a practical development route: compounds that already have sufficient manufacturing, toxicology, and regulatory groundwork can be evaluated more efficiently for mental disorders or alcohol addiction, potentially speeding translation to patients.

Three NIH Institutes jointly sponsor and encourage applications under this announcement: the National Institute of Mental Health (NIMH), the National Institute on Drug Abuse (NIDA), and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Collectively, they invite proposals that advance discovery, preclinical development, and proof-of-concept testing for rationally based candidate medications addressing mental disorders and substance use conditions, including alcohol addiction. The program also welcomes efforts to create novel ligands and other tools that sharpen the field's ability to interrogate targets and mechanisms, which can be just as important as advancing a single drug candidate because it improves the overall success rate of therapeutic development.

Because this is a cooperative agreement (U19), the structure implies a more collaborative relationship with NIH than a typical grant mechanism. Cooperative agreements generally involve substantial programmatic involvement from the funding agency, often including coordination, milestone-driven oversight, and active engagement to support progress and alignment with program goals. In plain terms, the expectation is not only strong science but also strong project management across multiple components, clear integration among participating investigators, and a translational plan that can withstand go/no-go decisions as data emerge.

Partnerships between academia and industry are strongly encouraged. That reflects the realities of drug development, where industry contributions can be decisive for medicinal chemistry optimization, formulation, manufacturing, regulatory planning, and the operational aspects of early clinical studies. At the same time, academic groups often bring deep disease expertise, novel target biology, cutting-edge models, and access to specialized clinical populations. Competitive applications would typically show how these complementary strengths are integrated into a single program with shared responsibilities rather than parallel, disconnected efforts.

Administratively, this opportunity was posted April 22, 2011, with an original and current closing date of February 22, 2013, and an archive date of March 25, 2013, under Funding Opportunity Number PAR-11-207. It falls under discretionary funding and uses the cooperative agreement instrument, with activity in the education and health category areas as listed. No cost sharing or matching is required. Eligible applicants include a wide range of U.S.-based organizations: public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (with or without 501(c)(3) status, other than institutions of higher education), small businesses, and for-profit organizations other than small businesses. Eligible federal agencies may also apply. Foreign organizations are not permitted as applicant organizations, although foreign components of U.S. organizations are allowed, which can matter for projects that rely on specialized overseas resources while maintaining a U.S. institutional lead.

The opportunity is associated with CFDA numbers 93.242 (Mental Health Research Grants), 93.273 (Alcohol Research Programs), and 93.279 (Drug Abuse and Addiction Research Programs), reflecting the cross-institute nature of the program. The full announcement was provided through the NIH grants guide (link in the source text), and NIH Office of Extramural Research (OER) webmaster contacts were listed for access or technical linking issues.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: DoD Bone Marrow Failure Idea Award

Previous opportunity: National Cooperative Drug Discovery and Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (UM1)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 11 207

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 11 207) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 207", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.